AstraZeneca PLC (ETR:ZEG)
Germany · Delayed Price · Currency is EUR | Market Cap | 201.14B |
| Revenue (ttm) | 48.11B |
| Net Income (ttm) | 7.06B |
| Shares Out | n/a |
| EPS (ttm) | 4.52 |
| PE Ratio | 28.48 |
| Forward PE | 15.61 |
| Dividend | 2.91 (2.25%) |
| Ex-Dividend Date | Aug 7, 2025 |
| Volume | 15,001 |
| Average Volume | 11,379 |
| Open | 130.15 |
| Previous Close | 129.40 |
| Day's Range | 129.70 - 131.40 |
| 52-Week Range | 111.00 - 147.85 |
| Beta | 0.17 |
| RSI | 38.80 |
| Earnings Date | Nov 6, 2025 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial numbers in USD Financial StatementsNews
CEO At Rigel Pharmaceuticals Acquires Company Stock Options Worth $388K
A substantial acquisition of company stock options by RAUL RODRIGUEZ , CEO at Rigel Pharmaceuticals (NASDAQ: RIGL) was reported on September 17, based on a new SEC filing. What Happened: In a Form 4 ...
Raymond Furey At Rigel Pharmaceuticals Secures Company Stock Options: $90K Acquired
A substantial acquisition of company stock options by Raymond Furey , EVP at Rigel Pharmaceuticals (NASDAQ: RIGL) was reported on September 17, based on a new SEC filing. What Happened: Revealed in a...
Lisa Rojkjaer Enhances Portfolio With Rigel Pharmaceuticals Stock Options: $90K Acquired
A noteworthy insider acquisition was disclosed on September 17, as Rojkjaer, EVP at Rigel Pharmaceuticals (NASDAQ: RIGL), reported the acquisition of stock options for 7,394 shares. What Happened: Re...
Significant Move: David Santos Invests $90K In Rigel Pharmaceuticals Stock Options
On September 17, Santos, EVP at Rigel Pharmaceuticals (NASDAQ: RIGL), executed a strategic insider move by acquiring stock options for 7,394 shares. What Happened: In a recent Form 4 filing with the ...
Dean Schorno Makes Strategic Play: Invests $90K In Rigel Pharmaceuticals Stock Options
In a new SEC filing on September 17, it was unveiled that Schorno, EVP & Chief Financial Officer at Rigel Pharmaceuticals (NASDAQ: RIGL), acquired stock options for 7,394 shares. What Happened: Schor...
AstraZeneca (AZN) Reinforces Airsupra Benefits with New Clinical Data
AstraZeneca (AZN) Reinforces Airsupra Benefits with New Clinical Data
AstraZeneca : AIRSUPRA Gains FDA Label Update After Strong Results In Mild Asthma Patients
(RTTNews) - AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) announced a major update to the U.S. prescribing information for AIRSUPRA, following new clinical evidence from the BATURA study. This Phase IIIb t...
Irelands pharma sector is world class, but why dont we have a Novo Nordisk to take our success to the next level?
Denmark has Novo Nordisk, France has Sanofi, Switzerland boasts both Roche and Novartis, while Germany has Bayer. Its a somewhat troubled relationship, but Britain has AstraZeneca.
AstraZeneca's Fasenra Falls Short In Smoker's Lung Trial
AstraZeneca Plc (NASDAQ: AZN) released on Wednesday topline data from RESOLUTE Phase 3 trial of Fasenra (benralizumab). AZN is showing upward bias. Get the complete picture here. Fasenra, despite sho...
AstraZeneca's Fasenra Falls Short In Smoker's Lung Trial
AstraZeneca Plc AZN released on Wednesday topline data from RESOLUTE Phase 3 trial of Fasenra (benralizumab).
AstraZeneca's (AZN) Fasenra COPD Trial Misses Key Endpoint
AstraZeneca's (AZN) Fasenra COPD Trial Misses Key Endpoint
AstraZeneca (AZN) Advances Saphnelo Injectable in Key Phase 3 Trial
AstraZeneca (AZN) Advances Saphnelo Injectable in Key Phase 3 Trial
AstraZeneca fails to meet main goal in lung disease trial
AstraZeneca’s Fasenra misses primary endpoint in COPD late-stage trial. Read more here.
AstraZeneca posts late-stage trial win for injectable Saphnelo in SLE
AstraZeneca (AZN) Reports Positive Phase III TULIP-SC Trial Results for Saphnelo
AstraZeneca (AZN) Reports Positive Phase III TULIP-SC Trial Results for Saphnelo
SAPHNELO self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from a pre-specified interim analysis of the Phase III TULIP-SC trial in patients with systemic lupus erythematosus (SLE) showed that the...
AstraZeneca's asthma drug fails main goal of COPD study
AstraZeneca said on Wednesday that its asthma drug Fasenra failed the main goal of a late-stage study in patients with chronic obstructive pulmonary disease (COPD).
Notable ETF Inflow Detected - SPDW, ASML, SAP, AZN
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR Portfolio Developed World ex-US ETF (Symbol: SPDW) where we have ...
Who benefits if NHS drug prices soar? Donald Trump and big pharma. Just one more way he’s menacing Britain | Polly Toynbee
The NHS needs cheap drugs, and our economy needs a thriving pharma industry. The president threatens both – no wonder Labour is grovelling to him Governing in the era of Donald Trump has been Labour’s...
Big pharma firms have paused nearly £2bn in UK investments this year
Government’s plans in disarray before Trump talks as MSD, Eli Lilly and AstraZeneca moves prompt job fears Big pharmaceutical companies have ditched or paused nearly £2bn in planned UK investments so ...
AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit
The U.K.-based AstraZeneca Plc (NASDAQ: AZN) paused a planned 200 million pounds ($271.26 million) investment in its Cambridge research site. AstraZeneca spokesperson told Reuters the company regular...
AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit
The U.K.-based AstraZeneca Plc AZN paused a planned 200 million pounds ($271.26 million) investment in its Cambridge research site.
AstraZeneca shares down 3% after rating cut, UK investment pause
AstraZeneca shares fell as much as 3.4% on Monday, their steepest drop since May, after Handelsbanken cut its rating on the drugmaker and Reuters reported the company had paused a major investment in ...
AstraZeneca Pauses Plans for $271 Million Expansion of U.K. Site
How the UK fell out with big pharma
The U.K. is in the midst of a falling out with big pharma over drug pricing. Merck has walked away from a 1 billion facility in London and pulled its research activities altogether. Now Eli Lilly, San...